Overview
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
Eligibility
Inclusion Criteria:
- Has cognitive ability to provide informed consent
- Aged 22 years or older
- Hospitalized with hypoxemia/respiratory distress
- Diagnosis of COPD
- Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
- Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)
Exclusion Criteria:
- Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
- Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
- Patient receiving end of life care
- Nasal or facial conditions precluding use of nasal high flow
- Pregnancy or breastfeeding
- Cognitive impairment or impaired consciousness precluding informed consent
- Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
- Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
- The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator
- Has already participated in this clinical trial